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Abstract
The pharyngeal-cervical-brachial (PCB) variant of Guillain-Barré syndrome (GBS) is very rare. It
is characterized by weakness of the upper extremities associated with bulbar symptoms and
facial diplegia. Documented cases were post-infectious, a post-vaccination occurrence has not
been documented in the available literature. Even rarer is the occurrence of any variant of GBS
following the mumps measles rubella (MMR) vaccine. The neurophysiological hallmark of PCB
variant of GBS is a combination of myelinopathy and axonopathy, hence, its consideration as a
subtype of the acute motor axonal neuropathy (AMAN) variant. It should be suspected in any
case of acute-onset flaccid symmetrical weakness of the upper extremities, as early diagnosis
and treatment are key to preventing fatal bulbar weakness. Here we report a case of a middle-
aged man, who presented with features of PCB a fortnight after being vaccinated for MMR.
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Introduction
Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculopathy that is
characterized by an acute-onset symmetrical flaccid muscle weakness with decreased or absent
deep tendon reflexes. Pharyngeal-cervical-brachial (PCB) variant of GBS is a localized variant
that presents with facial palsy, dysarthria, or dysphagia in addition to the weakness of the
upper extremity and areflexia of the upper limbs [1]. These features should not occur in the
settings of ophthalmoplegia, ataxia, altered consciousness, and prominent lower limb
weakness. The PCB variant of GBS is a rare variant of the disease whose pathological hallmark
is both demyelinating and axonal neuropathy [2].
Although two-thirds of cases of GBS are associated with antecedent infections, most of which
are sporadic, other precipitants include surgery, pregnancy, cancer, and vaccinations [3].
However, post-vaccination GBS is not very common. Cases of localized variants of GBS
following vaccination are even rarer. We report a case of PCB variant of GBS in a native African
following mumps measles rubella (MMR) vaccination.
Case Presentation
A 55-year-old man presented with a three-day history of weakness of both upper extremities,
which was noticed initially as difficulty in handling cutlery, which then progressed to difficulty
with lifting both upper limbs. He also complained of a worsening moderate to severe pain
around the neck and shoulders. The symptoms prompted his presentation to the ER, from
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where he was referred to the neurology outpatient department. A week before, he had
complained of a fleeting tingling sensation in the feet which had resolved spontaneously. He
had no prior fever, sore throat, diarrhea, surgery, or any other recent travel. He did not
consume canned food, not an IV drug user, and drank alcohol on social occasions. Two weeks
prior, he had received a vaccination for MMR. He had no underlying diabetes but took
amlodipine for his hypertension.
His initial evaluation revealed symmetric flaccid paresis of both upper limbs with a total loss of
handgrip bilaterally. His proximal muscle strength in the upper extremities was Medical
Research Council (MRC) grade 4, and across all muscle groups in the lower legs was MRC grade
4. The neck flexors were weaker than the extensors at grade 3- and grade 3+, respectively. There
was no muscle atrophy. The gag reflex was absent but there was no swallowing difficulty. There
was no evident weakness of the respiratory muscles. He had no objective sensory findings. His
peak flow rate was normal.
His cerebrospinal fluid (CSF) analysis done the following day showed no cytoalbumin
dissociation (Table 1).
Parameters Values Lab reference
Appearance Clear colorless Clear colorless
Supernatant Clear Clear
White cell count (mm3) Nil 0-5
Red cell count (mm3) Nil Nil
Protein (mg/dL) 38.13 15-45
Sugar (mmol/L) 3.16 2.22-3.89
Gram stain No organism Nil
TABLE 1: Routine CSF analysis.
CSF, cerebrospinal fluid
His first electrodiagnostic study showed conduction block of the right ulnar and left median
compound motor action potential (CMAP) as can be seen in Table 2 and delay of the left median
and both ulnar distal motor latencies (profound on the right). The median and ulnar F waves
were absent. The right and left spinal accessory CMAPs amplitudes were decreased. Other blood
works were within normal limits. He was commenced on intravenous immunoglobulin (IVIG) at
40 g daily for three days. Furthermore, we started carbamazepine at 200 mg twice daily in
addition to oral tramadol (50 mg twice daily) and diclofenac (50 mg twice daily) to achieve
adequate pain control. The patient commenced physiotherapy. A few days after admission, he
developed diplopia, facial diplegia, and dysarthria, all of which resolved within a fortnight of
onset. However, the proximal muscles of the upper limbs took a while to recover fully. After six
weeks, his electrodiagnostic study was repeated, and it showed average values in all the nerves.
The conduction block of the ulnar nerve had resolved (reversible conduction block) except for
both spinal accessory nerves (Table 2). Needle electromyogram (EMG) that was performed on
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day 90 revealed neurogenic motor unit potential (MUP) with reduced activation and weak
recruitment pattern of the right trapezius muscle and the left rhomboid muscles (Figures 1-2).
Nerve conduction parameters Day 3 Day 45 Day 90
Right median CMAP amplitude (mV)-Distal (Proximal) 9.65 (9.05) 10.87 (9.96) NP
Left median CMAP amplitude (mV)-Distal (Proximal) 9.30 (3.80) 9.39 (7.96) NP
Right median DML (ms) 3.10 3.18 NP
Left median DML (ms) 4.22 3.26 NP  
Right median motor CV (m/s)  39.22 63.64 NP
Left median motor CV (m/s)  75.90 62.50 NP
Right ulnar CMAP amplitude (mV)-Distal (Proximal) 7.65 (--)  3.35 (3.22)  NP
Left ulnar CMAP amplitude (mV)-Distal (Proximal) 2.07 (0.41) 3.42 (3.04) NP
Right ulnar DML (ms) 15.16 2.92 NP
Left ulnar DML (ms) 4.22 3.10 NP
Right ulnar motor CV (m/s) -- 32.24 NP
Left ulnar motor CV (m/s) 39.86 32.74 NP
Right spinal accessory amplitude (mV) 2.66 0.11 6.92
Left spinal accessory amplitude (mV) 2.54 0.03 1.72
Right median SNAP onset latency (ms) 2.70 2.39 NP
Left median SNAP onset latency (ms) 2.90 2.30 NP
Right ulnar SNAP onset latency (ms) 2.48  2.30  NP
Left ulnar SNAP onset latency (ms) 2.54 2.06 NP
Right median F wave (min V) -  28.26  NP
Left median F wave (min V) - 28.70 NP
Right ulnar F wave (min V) - 32.24  NP
Left ulnar F wave (min V) - 32.74 NP
TABLE 2: Serial nerve conduction parameters of the patient.
NP, not performed; CMAP, compound motor action potential; DML, distal motor latency; CV, conduction velocity; SNAP, sensory nerve
action potential
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FIGURE 1: Needle EMG of the right trapezius showing
neurogenic MUPs and increased polyphasia.
EMG, electromyogram; MUPs, motor unit potentials
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FIGURE 2: Needle EMG of the left rhomboid muscles showing
neurogenic MUPs.
EMG, electromyogram; MUPs, motor unit potentials
At 90 days after onset, his right accessory nerve had recovered, but the left accessory nerve
recovery lagged, showing temporal dispersion and decreased amplitude (Figure 3).
FIGURE 3: Right and left spinal accessory CMAPs at day 90.
CMAP, compound motor action potential
The patient eventually made a progressive full recovery over the following months. His
neurological evaluation at six months revealed no deficit.
Discussion
Patients with the PCB variant of GBS typically present with rapidly progressive oropharyngeal
and cervicobrachial weakness associated with areflexia in the upper limbs and the presence of
monospecific IgG anti-GT1a antibodies in the serum is typical [4]. However, the association
with GM1b and GD1a has also been described. The electrophysiological hallmark of PCB is
axonal conduction failure, and it is regarded as a continuation of acute motor axonal
neuropathy (AMAN) variant of GBS [2, 5]. The clinical and electrophysiological profile of our
patient was typical of PCB although we did not test anti-ganglioside antibodies as it is not
required for diagnosis. The presence of diplopia in our patient suggested an ophthalmoparesis
2020 Taiwo et al. Cureus 12(8): e9804. DOI 10.7759/cureus.9804 5 of 7
which has been found in about 40% of cases [4]. This variant of GBS is rare [6]. But rarer still is
the association with vaccination. Hall et al. reported a case of PCB in a middle-aged man who
had Vibrio cholerae vaccination but reports of post-vaccination PCB variant of GBS are scarce
globally [1]. We are not aware of similar cases in sub-Saharan Africa.
Most cases of PCB variant of GBS in the literature are post-infectious. Nagashima et al. found a
preceding infection in all the 100 patients with PCB in their study [4]. Seventy-one percent had
a prior respiratory tract infection, and 30% had preceding diarrhea. Of this cohort,
Campylobacter jejuni was the most common antecedent infectious agent (30%) followed by
Cytomegalovirus (6%), while Epstein-Barr virus, Mycoplasma pneumoniae, and Hemophilus
influenza accounted for 7%. Prior dengue fever has also been reported as a precursor of PCB [7].
Influenza vaccine is the most common antecedent vaccine that accounted for most post-
vaccination GBS. The incidence of GBS rose by more than nine-fold during the 1976 flu
vaccination season with the influenza A/H1N1, although no significant increase in GBS cases
been witnessed since then [3]. MMR vaccine, hepatitis B vaccine, polio vaccine and diphtheria,
tetanus, and pertussis (DTP) vaccines have been implicated as causes of post-vaccination GBS
even though a direct linkage of GBS with MMR vaccine was not found in a Korean
population [8]. The causal relationship (development of symptoms within six weeks of
receiving the vaccine) and the absence of preceding alternative events make ours a particular
case of post-vaccination PCB according to the WHO adverse events following immunization
(AEFI) criteria [9].
The clinical course of PCB should be acute and monophasic [2]. Our patient’s disease evolved
rapidly over days and plateau at two weeks. His bulbar and facial symptoms ultimately
improved over 14 days following IVIG administration, albeit, his shoulder weakness took a
while before total recovery. We attributed this to the axonal injury in the spinal accessory nerve
evidenced by the neurogenic MUPs in the shoulder muscles. Pain is another common feature of
GBS; as in our patient, a deep aching pain may be present in weakened muscles that patients
could liken to sore, over-exercised muscles [4]. Dysesthesia pain in the neck and shoulders,
which worsens over days, could reflect sensory nerve fiber involvement.
Conclusions
Pharyngeal-cervical-brachial variant of GBS is a rare variant of the disease but its precipitation
by vaccination is rarer. While the response to IVIG is typical for post-infections cases, it is
unclear if the time to nadir and the response to IVIG are similar in post-vaccination cases.
Furthermore, this variant of GBS should be remembered and ruled out, in patients who present
with oropharyngeal and cervicobrachial weakness. Electrophysiology and CSF analysis are
useful in diagnosis, but initial normal values do not rule out the disease. Clinical diagnosis is
paramount.
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